FAIRplus logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 12
Grant agreement number
802750

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
3 996 150
EFPIA in kind
4 232 500
Total Cost
8 228 650

Summary

The vast amounts of data generated in life science research have the potential to add to our understanding of disease and help advance drug development. Yet most data is hidden away in proprietary databases and stored in different formats. The goal of FAIRplus is to deliver guidelines and tools to facilitate the application of ‘FAIR’ principles to data from certain IMI projects and datasets from pharmaceutical companies. FAIR stands for ‘findable, accessible, interoperable, reusable’. The project will therefore make it easier for other researchers to find the data and integrate it into their own research. The project will also organise training courses for data scientists in academia, small and medium-sized enterprises (SMEs) and pharmaceutical companies. Ultimately, the project hopes to change the culture of data management in the life sciences sector.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Barcelona Supercomputing Center - Centro Nacional De Supercomputacion, Barcelona, Spain
  • European Molecular Biology Laboratory, Heidelberg, Germany
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain
  • Heriot-Watt University, Edinburgh, United Kingdom
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • The University Of Manchester, Manchester, United Kingdom
  • Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg
  • Universite Paul Sabatier Toulouse Iii, Toulouse, France
  • Universiteit Maastricht, Maastricht, Netherlands
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Open Phacts Foundation Lbg, Cambridge, United Kingdom
  • Stichting Lygature, Utrecht, Netherlands
  • The Hyve BV, Utrecht, Netherlands
Associated partners
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Novartis Pharma AG, Basel, Switzerland
Third parties
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France

CONTACT

Project coordinator
Serena SCOLLEN
EUROPEAN MOLECULAR BIOLOGY LABORATORY
serena.scollen[at]elixir-europe.org